Special Issue "Emerging Therapeutic Candidates for Stroke Treatment"
Deadline for manuscript submissions: closed (10 November 2023) | Viewed by 3880
Interests: brain ischemia; stroke; cardiac arrest; neuroinflammation; neuroprotection; brain stimulation; microglia; astrocyte; ER stress; UPR; proteostasis; SUMO
Stroke continues to be a leading cause of death and long-term disability worldwide. There are two main types of stroke: ischemic and hemorrhagic stroke. Mechanical/pharmacologic reperfusion therapy is currently the most effective treatment for ischemic stroke, while the medical intervention for hemorrhagic stroke aims to remove the hematoma and stop bleeding, usually through a surgical procedure. Although these treatments are effective, they have a relatively narrow time window and are not readily available in all hospitals. Furthermore, only a portion of stroke patients are eligible for these treatments, and of those who are treated without delay, many do not regain functional independence.
Obviously, current therapeutic options for stroke patients, especially pharmacologic interventions, are very limited. In this regard, at least two categories of potential stroke therapeutics are urgently needed. The first category is cerebroprotective adjuvant agents that can decelerate the progression of stroke-induced brain injury and thus extend the therapeutic window. The second could be administered to augment the beneficial effects of acute treatment and/or promote brain recovery during the chronic stroke phase. Decades of basic research have identified numerous potential targets for stroke therapy, and many have shown preclinical efficacy. This Special Issue is dedicated to publishing both original research articles and reviews with a focus on emerging therapeutic candidates for stroke treatment. We hope that this collection will serve as a valuable resource in the search for novel stroke treatments that will ultimately improve the quality of life of patients suffering from stroke.
Dr. Wei Yang
Dr. Huaxin Sheng
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- small molecules
- drug discovery